Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Bromopride API Manufacturers & Suppliers
4 verified results
All Bromopride data. Full access. Full negotiation power
Commercial-scale Suppliers
All certificates
Employees: 19
All certificates
Employees: 50
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Bromopride | CAS No: 4093-35-0 | GMP-certified suppliers
A medication that treats nausea, vomiting, postoperative nausea, gastroesophageal reflux disease, and prepares patients for gastrointestinal endoscopy and radiographic procedures.
Therapeutic categories
Primary indications
- Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract
Product Snapshot
- Bromopride is available in multiple oral formulations including coated tablets, pills, capsules, and solutions, as well as parenteral forms for intramuscular and intravenous administration
- It is primarily indicated for the management of nausea and vomiting, gastroesophageal reflux disease, and for use in endoscopy preparation and radiographic procedures
- Bromopride is currently in an investigational status and has not yet received regulatory approval
Clinical Overview
Clinically, bromopride is indicated for the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV). It is also utilized in managing gastroesophageal reflux disease (GERD) and as a preparatory agent for gastrointestinal endoscopy and radiographic procedures. Despite its applications, bromopride is not approved for use in the United States or the United Kingdom and is categorized as investigational in some regions.
The mechanism of action involves antagonism at dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the central nervous system. This antagonism reduces dopamine-mediated emetic signaling and facilitates enhanced gastrointestinal motility through modulation of gastric smooth muscle activity, promoting accelerated gastric emptying and improved transit.
Pharmacokinetic parameters for bromopride are not fully elucidated in the available data; however, as with other benzamide derivatives, it is expected to undergo hepatic metabolism with renal excretion of metabolites and unchanged drug. The drug’s absorption and systemic distribution profile have not been comprehensively documented.
Safety considerations include the potential for extrapyramidal symptoms due to central dopamine receptor blockade, as observed with related compounds. Other adverse effects may include sedation or gastrointestinal disturbances. Given the dopaminergic activity, caution is advised in patients with Parkinsonian syndromes or those on other dopamine antagonists.
Bromopride’s quality and purity standards for active pharmaceutical ingredient (API) procurement should align with recognized pharmacopeial criteria, ensuring appropriate chemical identity, assay, and impurity profiles. Suppliers should provide full documentation confirming compliance with regulatory guidelines, including stability and batch-to-batch consistency, to support development and manufacturing activities.
Identification & chemistry
| Generic name | Bromopride |
|---|---|
| Molecule type | Small molecule |
| CAS | 4093-35-0 |
| UNII | 75473V2YZK |
| DrugBank ID | DB09018 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Dopamine D2 receptor | Humans | antagonist |
ADME / PK
| Protein binding | 40%. |
|---|---|
| Metabolism | Hepatic. |
| Clearance | Renal, 10-14% as original compound. |
Formulation & handling
- Bromopride is a small molecule amenable to both oral and parenteral (intramuscular, intravenous) administration.
- The moderate LogP (1.56) indicates balanced lipophilicity suitable for systemic absorption without excessive lipophilic retention.
- Its low water solubility (~0.241 g/L) suggests formulation strategies should consider solubilization or suspension approaches for oral or injectable forms.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient has been on the market in the United States since the early 1980s, with key patents expiring by the late 1990s, indicating a mature market with availability of generic versions. |
|---|
Supply Chain
| Supply chain summary | Bromopride is supported by multiple originator patents filed in the early 1980s, indicating that original brand formulations have long been established. Branded products are distributed across key markets including the US and EU, as well as other regions. Given the patent expirations dating back several decades, the market is likely characterized by the presence of generic competition. |
|---|
Bromopride is a type of Dopamine antagonists
Dopamine antagonists belong to the pharmaceutical API subcategory that plays a crucial role in the management of various medical conditions. These compounds act by blocking dopamine receptors, which are responsible for transmitting signals in the brain. By inhibiting dopamine activity, dopamine antagonists exhibit diverse therapeutic effects.
One significant application of dopamine antagonists is in the treatment of psychiatric disorders. They are commonly used to manage schizophrenia, a severe mental disorder characterized by hallucinations, delusions, and disorganized thinking. Dopamine antagonists help reduce the symptoms of schizophrenia by normalizing the excessive dopamine activity in the brain.
Additionally, these pharmaceutical APIs find application in managing other conditions such as bipolar disorder, nausea, vomiting, and certain movement disorders. Dopamine antagonists can effectively alleviate the symptoms associated with these conditions by modulating dopamine levels and restoring the balance in neural signaling.
Pharmaceutical companies utilize advanced synthesis and purification techniques to produce high-quality dopamine antagonists for use as active ingredients in various medications. These APIs undergo stringent quality control measures to ensure their safety, efficacy, and compliance with regulatory standards.
In conclusion, dopamine antagonists constitute an important subcategory of pharmaceutical APIs, offering valuable therapeutic benefits for psychiatric disorders, nausea, vomiting, and movement disorders. Their ability to selectively block dopamine receptors makes them indispensable in modern medicine, enabling improved patient outcomes and quality of life.
Bromopride (Dopamine antagonists), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Bromopride API manufacturers & distributors
Compare qualified Bromopride API suppliers worldwide. We currently have 4 companies offering Bromopride API, with manufacturing taking place in 4 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ICROM | Producer | Italy | Italy | CoA, GMP, USDMF | 19 products |
| LEBSA | Producer | Spain | Spain | BSE/TSE, CoA, Other, EDMF/ASMF, GDP, GMP, Other, Other, ISO9001, MSDS | 18 products |
| SETV Global | Producer | India | India | CoA, FDA, GMP | 515 products |
| Veeprho Group | Producer | Czech Republic | Czech Republic | CoA | 144 products |
When sending a request, specify which Bromopride API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Bromopride API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
